Corpus callosum in neurodegenerative diseases: findings in Parkinson's disease.
Identifieur interne : 001298 ( PubMed/Corpus ); précédent : 001297; suivant : 001299Corpus callosum in neurodegenerative diseases: findings in Parkinson's disease.
Auteurs : Katie Wiltshire ; Sheri Foster ; Jeffrey A. Kaye ; Brent J. Small ; Richard CamicioliSource :
- Dementia and geriatric cognitive disorders [ 1420-8008 ] ; 2005.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Alzheimer Disease (pathology), Atrophy, Corpus Callosum (pathology), Dementia (complications), Dementia (pathology), Diagnosis, Differential, Diffusion Magnetic Resonance Imaging, Female, Humans, Male, Middle Aged, Neurodegenerative Diseases (pathology), Parkinson Disease (complications), Parkinson Disease (pathology), Severity of Illness Index, Supranuclear Palsy, Progressive (pathology).
- MESH :
- complications : Dementia, Parkinson Disease.
- pathology : Alzheimer Disease, Corpus Callosum, Dementia, Neurodegenerative Diseases, Parkinson Disease, Supranuclear Palsy, Progressive.
- Aged, Aged, 80 and over, Atrophy, Diagnosis, Differential, Diffusion Magnetic Resonance Imaging, Female, Humans, Male, Middle Aged, Severity of Illness Index.
Abstract
Corpus callosum area has been examined in neurodegenerative diseases as a marker for cortical pathology and for differential diagnosis; however, it has not been examined in Parkinson's disease (PD). We compared callosal area in patients with PD and PD with dementia (PDD) to healthy controls and patients with Alzheimer's disease (AD). We subsequently compared our results to a meta-analysis of studies examining callosal area in AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). For the imaging study, midsagittal T1-weighted MRIs were analyzed and the callosal area was determined in patients with PD (n = 24), PDD (n = 25), AD (n = 16) and controls (n = 27). The meta-analysis combined results from all publications (Medline or PubMed) representing unique samples and measuring callosal area in AD, FTD, PSP, and CBD. We found that PD and PDD patients did not show statistically significant callosal atrophy compared to controls (effect size d, 95% CI, d = 0.13, -0.26 to 0.52, and d = 0.05, -0.44 to 0.33, respectively) or AD. The AD patients had a significant loss of callosal area compared to controls (d = -0.58, -1.01 to -0.15). Dementia severity was correlated with total callosal atrophy in AD (R = 0.66, p < 0.01) but not in PDD patients (R = 0.18, p > 0.1). The meta-analysis revealed significant combined effect sizes for callosal atrophy of: AD (d = -1.03, -1.13 to -0.93), FTD (d = -1.21, -1.56 to -0.86), PSP (d = -1.09, -1.38 to -0.81), and CBD (d = -1.80, -2.18 to -1.43). We conclude that PD and PDD patients do not have callosal atrophy in contrast to other neurodegenerative diseases, including AD. Callosal atrophy was correlated with dementia severity in patients with AD but not PDD.
DOI: 10.1159/000088526
PubMed: 16192724
Links to Exploration step
pubmed:16192724Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Corpus callosum in neurodegenerative diseases: findings in Parkinson's disease.</title>
<author><name sortKey="Wiltshire, Katie" sort="Wiltshire, Katie" uniqKey="Wiltshire K" first="Katie" last="Wiltshire">Katie Wiltshire</name>
<affiliation><nlm:affiliation>University of Alberta, Edmonton, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Foster, Sheri" sort="Foster, Sheri" uniqKey="Foster S" first="Sheri" last="Foster">Sheri Foster</name>
</author>
<author><name sortKey="Kaye, Jeffrey A" sort="Kaye, Jeffrey A" uniqKey="Kaye J" first="Jeffrey A" last="Kaye">Jeffrey A. Kaye</name>
</author>
<author><name sortKey="Small, Brent J" sort="Small, Brent J" uniqKey="Small B" first="Brent J" last="Small">Brent J. Small</name>
</author>
<author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:16192724</idno>
<idno type="pmid">16192724</idno>
<idno type="doi">10.1159/000088526</idno>
<idno type="wicri:Area/PubMed/Corpus">001298</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001298</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Corpus callosum in neurodegenerative diseases: findings in Parkinson's disease.</title>
<author><name sortKey="Wiltshire, Katie" sort="Wiltshire, Katie" uniqKey="Wiltshire K" first="Katie" last="Wiltshire">Katie Wiltshire</name>
<affiliation><nlm:affiliation>University of Alberta, Edmonton, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Foster, Sheri" sort="Foster, Sheri" uniqKey="Foster S" first="Sheri" last="Foster">Sheri Foster</name>
</author>
<author><name sortKey="Kaye, Jeffrey A" sort="Kaye, Jeffrey A" uniqKey="Kaye J" first="Jeffrey A" last="Kaye">Jeffrey A. Kaye</name>
</author>
<author><name sortKey="Small, Brent J" sort="Small, Brent J" uniqKey="Small B" first="Brent J" last="Small">Brent J. Small</name>
</author>
<author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name>
</author>
</analytic>
<series><title level="j">Dementia and geriatric cognitive disorders</title>
<idno type="ISSN">1420-8008</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Alzheimer Disease (pathology)</term>
<term>Atrophy</term>
<term>Corpus Callosum (pathology)</term>
<term>Dementia (complications)</term>
<term>Dementia (pathology)</term>
<term>Diagnosis, Differential</term>
<term>Diffusion Magnetic Resonance Imaging</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurodegenerative Diseases (pathology)</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (pathology)</term>
<term>Severity of Illness Index</term>
<term>Supranuclear Palsy, Progressive (pathology)</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Dementia</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Alzheimer Disease</term>
<term>Corpus Callosum</term>
<term>Dementia</term>
<term>Neurodegenerative Diseases</term>
<term>Parkinson Disease</term>
<term>Supranuclear Palsy, Progressive</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Atrophy</term>
<term>Diagnosis, Differential</term>
<term>Diffusion Magnetic Resonance Imaging</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Severity of Illness Index</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Corpus callosum area has been examined in neurodegenerative diseases as a marker for cortical pathology and for differential diagnosis; however, it has not been examined in Parkinson's disease (PD). We compared callosal area in patients with PD and PD with dementia (PDD) to healthy controls and patients with Alzheimer's disease (AD). We subsequently compared our results to a meta-analysis of studies examining callosal area in AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). For the imaging study, midsagittal T1-weighted MRIs were analyzed and the callosal area was determined in patients with PD (n = 24), PDD (n = 25), AD (n = 16) and controls (n = 27). The meta-analysis combined results from all publications (Medline or PubMed) representing unique samples and measuring callosal area in AD, FTD, PSP, and CBD. We found that PD and PDD patients did not show statistically significant callosal atrophy compared to controls (effect size d, 95% CI, d = 0.13, -0.26 to 0.52, and d = 0.05, -0.44 to 0.33, respectively) or AD. The AD patients had a significant loss of callosal area compared to controls (d = -0.58, -1.01 to -0.15). Dementia severity was correlated with total callosal atrophy in AD (R = 0.66, p < 0.01) but not in PDD patients (R = 0.18, p > 0.1). The meta-analysis revealed significant combined effect sizes for callosal atrophy of: AD (d = -1.03, -1.13 to -0.93), FTD (d = -1.21, -1.56 to -0.86), PSP (d = -1.09, -1.38 to -0.81), and CBD (d = -1.80, -2.18 to -1.43). We conclude that PD and PDD patients do not have callosal atrophy in contrast to other neurodegenerative diseases, including AD. Callosal atrophy was correlated with dementia severity in patients with AD but not PDD.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16192724</PMID>
<DateCreated><Year>2005</Year>
<Month>11</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted><Year>2006</Year>
<Month>01</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2008</Year>
<Month>03</Month>
<Day>24</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1420-8008</ISSN>
<JournalIssue CitedMedium="Print"><Volume>20</Volume>
<Issue>6</Issue>
<PubDate><Year>2005</Year>
</PubDate>
</JournalIssue>
<Title>Dementia and geriatric cognitive disorders</Title>
<ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation>
</Journal>
<ArticleTitle>Corpus callosum in neurodegenerative diseases: findings in Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>345-51</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Corpus callosum area has been examined in neurodegenerative diseases as a marker for cortical pathology and for differential diagnosis; however, it has not been examined in Parkinson's disease (PD). We compared callosal area in patients with PD and PD with dementia (PDD) to healthy controls and patients with Alzheimer's disease (AD). We subsequently compared our results to a meta-analysis of studies examining callosal area in AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). For the imaging study, midsagittal T1-weighted MRIs were analyzed and the callosal area was determined in patients with PD (n = 24), PDD (n = 25), AD (n = 16) and controls (n = 27). The meta-analysis combined results from all publications (Medline or PubMed) representing unique samples and measuring callosal area in AD, FTD, PSP, and CBD. We found that PD and PDD patients did not show statistically significant callosal atrophy compared to controls (effect size d, 95% CI, d = 0.13, -0.26 to 0.52, and d = 0.05, -0.44 to 0.33, respectively) or AD. The AD patients had a significant loss of callosal area compared to controls (d = -0.58, -1.01 to -0.15). Dementia severity was correlated with total callosal atrophy in AD (R = 0.66, p < 0.01) but not in PDD patients (R = 0.18, p > 0.1). The meta-analysis revealed significant combined effect sizes for callosal atrophy of: AD (d = -1.03, -1.13 to -0.93), FTD (d = -1.21, -1.56 to -0.86), PSP (d = -1.09, -1.38 to -0.81), and CBD (d = -1.80, -2.18 to -1.43). We conclude that PD and PDD patients do not have callosal atrophy in contrast to other neurodegenerative diseases, including AD. Callosal atrophy was correlated with dementia severity in patients with AD but not PDD.</AbstractText>
<CopyrightInformation>2005 S. Karger AG, Basel</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wiltshire</LastName>
<ForeName>Katie</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>University of Alberta, Edmonton, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Foster</LastName>
<ForeName>Sheri</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kaye</LastName>
<ForeName>Jeffrey A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Small</LastName>
<ForeName>Brent J</ForeName>
<Initials>BJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Camicioli</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>AG08017</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>M01 RR000334</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D017418">Meta-Analysis</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2005</Year>
<Month>09</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Dement Geriatr Cogn Disord</MedlineTA>
<NlmUniqueID>9705200</NlmUniqueID>
<ISSNLinking>1420-8008</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003337" MajorTopicYN="N">Corpus Callosum</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D038524" MajorTopicYN="N">Diffusion Magnetic Resonance Imaging</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2005</Year>
<Month>05</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>9</Month>
<Day>30</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>1</Month>
<Day>25</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>9</Month>
<Day>30</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16192724</ArticleId>
<ArticleId IdType="pii">88526</ArticleId>
<ArticleId IdType="doi">10.1159/000088526</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001298 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001298 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:16192724 |texte= Corpus callosum in neurodegenerative diseases: findings in Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16192724" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonCanadaV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |